Spring Education Exchange (SEE): Debating Curative Therapies for Sickle Cell Disease: Gene Therapy vs Allogeneic Transplant

Spring Education Exchange (SEE): Day 2, Session 8

Presented By: Misty Evans, DNP, APRN, CPNP-AC, BMTCN

Session Details: Day 2: May 15, Session 8 1:05 PM EST (12:05 PM CST/11:05 AM MST/10:05 AM PST)

Overview of Session: Sickle cell disease (SCD) is an inherited blood disorder caused by variants of the β-globin (HBB) gene, affecting approximately 300,000 people worldwide each year. This condition leads to complications such as pain from vaso-occlusive crises (VOCs), anemia, and end-organ damage, significantly impacting life expectancy and quality of life. Allogeneic hematopoietic stem cell transplant (HSCT) offers a curative option, particularly from HLA-identical sibling donors, but less than 20% of patients have a compatible sibling donor. Alternative donor options, such as haploidentical biological parents or siblings, have increased donor availability but come with risks like graft-versus-host disease (GVHD). Gene therapies have shown promising results in clinical trials, though long-term data and accessibility due to high costs remain challenges. This session will review the latest data on allogeneic HSCT and gene therapies as curative treatments for children, adolescents, and young adults with SCD.

Learning Outcomes:

• The learner will identify the different treatment modalities of allogeneic hematopoietic stem cell transplant for sickle cell disease.
• The learner will distinguish between the different gene therapies currently available for the treatment of sickle cell disease.
• The learner will evaluate the various risks and benefits associated with allogeneic hematopoietic stem cell transplant versus gene therapy for sickle cell disease.

This contains 2 sections:

1. Webinar Session Link
2. Post-Session Evaluation

Continuing Education Credit

APHON will provide 1 nursing continuing professional development (NCPD) contact hour(s) for the successful completion of this session. Successful completion requires attendance for the entire session and the completion of the post-session evaluation.

The Spring Education Exchange (SEE) sessions and post-session evaluations will be available for 30 days.

The Association for Pediatric Hematology Oncology Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. This provider is also approved by the California Board of Registered Nursing, Provider Number 14513.

None of the planners for this activity have relevant financial relationship(s) to disclose with ineligible companies.

FAQs: [Link to FAQ Page]

Questions or concerns? Contact education@aphon.org.

The APHON Spring Education Exchange is sponsored by ONCC.